AdvanCell
AdvanCell raises $112M Series C at $700M valuation
Quick Facts
AdvanCell: Series C Funding Round
AdvanCell has successfully raised $112M in Series C funding, reaching a valuation of $700M.
Company Overview
Radionuclide cancer therapies
Funding Details
The Series C round was led by Deerfield Management, with participation from Logos Capital.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2021
- Employees: 90+
- Category: HealthTech
Investment
AdvanCell plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Deerfield Management: Verified investor in Series C
- Logos Capital: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
